Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 6, 2008, Pages 283-287

  Quetglas, Emilio García ^a   Campanero, Miguel Angel ^a   Sádaba, Belén ^a   Escolar, Manuel ^a   Azanza, Jose Ramón ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Anticoagulants; Bioequivalence; Capsule; CAS 322 79 2; Triflusal

Indexed keywords

3 HYDROXY 4 TRIFLUOROMETHYLBENZOIC ACID; ANTITHROMBOCYTIC AGENT; DRUG METABOLITE; TRIFLUSAL;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRESCRIPTION; SCHUIRMANN METHOD; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STUDENT T TEST; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 46949086192     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296508     Document Type: Article

References (10)

1. McNeely W, Goa KL. Triflusal. Drugs 1998;55:823-833 (discussion 834-825).
2. Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jane F. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet. 1991;16:269-273.
3. Ferrari E, Reboldi G, Marenco P, D'Angelo L, Crema F, Ambrosoli L, et al. Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. Am J Ther. 1996;3:630-636.
4. Ramis J, Torrent J, Mis R, Conte L, Barbanoj MJ, Jane J, et al. Pharmacokinetics of triflusal after single and repeated doses in man. Int J Clin Pharmacol Ther Toxicol. 1990;28:344-349.
5. EMEA (European Agency for the Evaluation of Medicinal Products). CPMP (Committee for Propietary Medicinal Products). Note for guidance on the investigation of bioavailability and bioequivalence. London, July 2001.
6. Hauschke D, Steinijans VW and Diletti E, A distribution-free procedure for the statistical analysis of bioequivalence studies, Int J Clin Pharmacol Ther Toxicol, 1990;28:272-278.
7. Steinijans VW, Diletti E. Generalization of distribution-free confidence intervals for bioavailability ratios. Eur J Clin Pharmacol, 1985;28:185-188.
8. Chen ML, Lee SC, Ng MJ, Schuirmann DJ, Lesko LJ, Williams RL. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 2000;68:510-521.
9. Cho HY, Jeong TJ, Lee YB. Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-triflu-oromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. J Chromatogr B 2003;798:257-264.
10. FDA CEDER. March 2003. Guidance for industry. Bioavailability and Bioequivalence studies for orally administered drug products. General considerations.